HTAs and rare diseases: How to assess their cost-effectiveness

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

StandardStandard

HTAs and rare diseases: How to assess their cost-effectiveness. / Hughes, D.; Phillips, C.J.; Hughes, D.A.
Yn: Pharmaceuticals Policy and Law, Cyfrol 13, Rhif 3-4, 01.11.2011, t. 161-165.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

Hughes, D, Phillips, CJ & Hughes, DA 2011, 'HTAs and rare diseases: How to assess their cost-effectiveness', Pharmaceuticals Policy and Law, cyfrol. 13, rhif 3-4, tt. 161-165. https://doi.org/10.3233/PPL-2011-0321

APA

Hughes, D., Phillips, C. J., & Hughes, D. A. (2011). HTAs and rare diseases: How to assess their cost-effectiveness. Pharmaceuticals Policy and Law, 13(3-4), 161-165. https://doi.org/10.3233/PPL-2011-0321

CBE

Hughes D, Phillips CJ, Hughes DA. 2011. HTAs and rare diseases: How to assess their cost-effectiveness. Pharmaceuticals Policy and Law. 13(3-4):161-165. https://doi.org/10.3233/PPL-2011-0321

MLA

Hughes, D., C.J. Phillips a D.A. Hughes. "HTAs and rare diseases: How to assess their cost-effectiveness". Pharmaceuticals Policy and Law. 2011, 13(3-4). 161-165. https://doi.org/10.3233/PPL-2011-0321

VancouverVancouver

Hughes D, Phillips CJ, Hughes DA. HTAs and rare diseases: How to assess their cost-effectiveness. Pharmaceuticals Policy and Law. 2011 Tach 1;13(3-4):161-165. doi: 10.3233/PPL-2011-0321

Author

Hughes, D. ; Phillips, C.J. ; Hughes, D.A. / HTAs and rare diseases: How to assess their cost-effectiveness. Yn: Pharmaceuticals Policy and Law. 2011 ; Cyfrol 13, Rhif 3-4. tt. 161-165.

RIS

TY - JOUR

T1 - HTAs and rare diseases: How to assess their cost-effectiveness

AU - Hughes, D.

AU - Phillips, C.J.

AU - Hughes, D.A.

PY - 2011/11/1

Y1 - 2011/11/1

U2 - 10.3233/PPL-2011-0321

DO - 10.3233/PPL-2011-0321

M3 - Article

VL - 13

SP - 161

EP - 165

JO - Pharmaceuticals Policy and Law

JF - Pharmaceuticals Policy and Law

SN - 1389-2827

IS - 3-4

ER -